ArticleJournal of nanobiotechnology2026
NIR-II photothermal-amplified triple catalysis of a spherical mesoporous iron single-atom nanozyme for potentiating ferroptosis-based tumor therapy.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundSingle-atom nanozymes (SAzymes) generally trigger catalytic reactions in situ within tumor cells, generating toxic reactive oxygen species (ROS) that induce cell death through oxidative stress, thereby achieving catalytic tumor therapy. However, therapeutic efficacy is often limited by insufficient ROS levels and intrinsic cellular antioxidant defenses.
resultsThis study developed a spherical mesoporous iron-based single-atom nanozyme (Fe-SAzyme) modified with polyethylene glycol (PEG) and (4-carboxybutyl)triphenylphosphonium bromide (TPP), achieving photothermal amplification of catalytic activities to deliver antitumor therapeutic effects. Fe-SAzyme exhibited triple enzyme-mimetic activities-peroxidase-like, glutathione peroxidase-like, and catalase-like activity. It simultaneously generated ROS and oxygen while oxidizing glutathione to oxidized glutathione. This elevation in ROS levels and weakening of antioxidant defenses disrupted intracellular redox homeostasis, ultimately triggering a process known as ferroptosis. Density functional theory (DFT) calculations revealed that Fe-SAzyme exhibited a low energy barrier for hydroxyl radical generation and possessed a viable cyclic catalytic pathway. Additionally, Fe-SAzyme-TPP exhibited exceptional photothermal conversion capabilities under second near-infrared (NIR-II) irradiation, enabling its use in photothermal therapy (PTT), while simultaneously enhancing catalytic activity and thereby significantly improving tumor treatment efficacy. In vitro and in vivo experiments demonstrated that PEG and TPP-modified Fe-SAzyme exhibited outstanding antitumor efficacy, along with enhanced biocompatibility and targeting capabilities. Under NIR-II irradiation, photothermal therapy synergized with catalytic activities, significantly amplifying tumor suppression effects.
conclusionThis study proposed a combined antitumor strategy based on iron-based SAzymes, utilizing photothermal amplification to enhance catalytic activities in conjunction with PTT, thereby achieving ferroptosis-based antitumor effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.